Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

With their promise to transform disease trajectories, cell and gene therapies (CGTs) are bringing new hope to patients with ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...